A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate

作者：De Clercq Erik^*

来源：Expert Opinion on Pharmacotherapy, 2009, 10(17): 2935-2937.

DOI：10.1517/14656560903418467

• Combination therapy
• Emtricitabine
• Raltegravir
• Tenofovir disoproxil fumarate (TDF)
• Truvada(R)

A new drug combination regimen, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate (TDF), is described for the treatment of HIV-1 infection. This new drug combination regimen is applicable to the treatment of drug-naive HIV-1-infected patients. it extends the use of the drug combinations to a new class of anti-HIV drugs, i.e. raltegravir, targeted at a new site in the HIV-1 replicative cycle, namely the HIV-1 integrase. This opens new perspectives for the design of multiple drug combination regimens targeting different enzymes involved in HIV-1 replication, i.e. integrase and reverse transcriptase. These multiple (triple or quadruple) drug combinations should be aimed at once daily dosing.

• 出版日期2009-12
• 单位河北医科大学